- Home
- DGX vs CBOE Comparison
DGX vs CBOE Comparison
Compare DGX & CBOE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DGX | CBOE |
|---|---|---|
| Founded | 1967 | 1973 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.1B | 26.8B |
| IPO Year | 1996 | 2010 |
Fundamental Metrics
Financial Performance| Metric | DGX | CBOE |
|---|---|---|
| Price | $191.73 | $295.10 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 12 | 10 |
| Target Price | $208.92 | ★ $277.30 |
| AVG Volume (30 Days) | 646.7K | ★ 715.0K |
| Earning Date | 04-21-2026 | 05-01-2026 |
| Dividend Yield | ★ 1.74% | 0.98% |
| EPS Growth | 13.78 | ★ 44.52 |
| EPS | 8.75 | ★ 10.42 |
| Revenue | ★ $11,035,000,000.00 | $2,229,100,000.00 |
| Revenue This Year | $7.53 | N/A |
| Revenue Next Year | $3.77 | $4.59 |
| P/E Ratio | ★ $22.63 | $28.31 |
| Revenue Growth | 11.78 | ★ 239.31 |
| 52 Week Low | $160.02 | $207.75 |
| 52 Week High | $213.50 | $305.68 |
Technical Indicators
Market Signals| Indicator | DGX | CBOE |
|---|---|---|
| Relative Strength Index (RSI) | 37.45 | 58.81 |
| Support Level | $176.61 | $276.64 |
| Resistance Level | $191.91 | $297.10 |
| Average True Range (ATR) | 4.46 | 7.02 |
| MACD | -0.27 | 1.40 |
| Stochastic Oscillator | 10.95 | 76.53 |
Price Performance
Historical ComparisonAbout DGX Quest Diagnostics Incorporated
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
About CBOE Cboe Global Markets Inc.
Founded in 1973, Cboe controls the largest option exchange in the US, which provides around 60% of the firm's revenue. The company is best known for its proprietary S&P 500 and VIX index options, which it offers through an exclusive contract with S&P Global. The firm moved into US and European equities through the $3.4 billion acquisition of BATS in 2017. Cboe has continued to look to expand internationally, using acquisitions to build a presence in both Canada and Australia.